This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Jacobio Pharmaceuticals Co., Ltd.. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: Innovations of Zilong Xu in SHP2 Inhibitors
Introduction
Zilong Xu is a notable inventor based in Beijing, China, who has made significant contributions to the field of pharmacology through his innovative work on SHP2 inhibitors. His research focuses on novel compounds that hold potential for treating various disorders associated with SHP2 proteins.
Latest Patents
Zilong Xu holds a patent for his invention titled "Heterocyclic derivatives useful as SHP2 inhibitors." This patent details the synthesis and application of specific novel pyrazine derivatives that are aimed at treating SHP2-mediated disorders. More specifically, the invention emphasizes the efficacy of fused heterocyclic group derivatives as inhibitors of SHP2 and outlines methods for producing these compounds.
Career Highlights
Currently, Zilong Xu is associated with Jacobio Pharmaceuticals Co., Ltd., a company known for its commitment to pioneering research and development in drug discovery. His work has been pivotal in advancing the understanding of SHP2-related pathways and therapeutic interventions.
Collaborations
Throughout his career, Zilong Xu has collaborated with esteemed colleagues, including Cunbo Ma and Panliang Gao. These collaborations have further enriched his research, allowing for a more interdisciplinary approach to tackling complex medical challenges.
Conclusion
Zilong Xu's innovative work in the development of SHP2 inhibitors demonstrates the critical role of inventors in the advancement of medical science. His contributions not only enhance our understanding of biochemical mechanisms but also pave the way for new therapeutic options in treating serious disorders.